



## Hepatitis Vaccines: Immunization, Effectiveness and Future Challenges

Guest Editor:

**Dr. Muhammad Atif Zahoor**

Toronto Centre for Liver Disease,  
Toronto General Hospital  
Research Institute, University  
Health Network, Toronto, ON,  
Canada

Deadline for manuscript  
submissions:

**30 September 2024**

### Message from the Guest Editor

Viral hepatitis, or inflammation of the liver, is caused by a viral infection and remains a major human health problem worldwide. Many different viruses cause viral hepatitis, which includes, in alphabetical order, hepatitis A, B, C, D, and E. WHO's global hepatitis strategy aims to reduce new hepatitis infections by 90% and deaths by 65% between 2016 and 2030. To reduce the morbidity and mortality, protective vaccination for these hepatitis viruses remains the main goal of public health policy and is a key component of the global viral hepatitis elimination plan.

With this aim, in this Special Issue, we will summarize the current knowledge and aim to answer some of the many questions on viral hepatitis, their prevention through vaccination, vaccine effectiveness, and future challenges in this field. We invite the submission of original research and review articles that cover any aspect of viral hepatitis, prevention through vaccines, prophylactic and therapeutic vaccines, vaccine development and technology, vaccine immunity, etc.





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

**Journal Rank:** JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)